X hits on this document





10 / 10



HEPATOLOGY, November 2002

hepaitis C virus RNA and histological lesions in chronic hepatitis C. HEPA- TOLOGY 1998;27:1717-1722. 28. Khan KN, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Jap- anese patients. Alcohol Alcohol 2000;35:286-295. 29. Geissler M, Gesien A, Wands JR. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core pro- tein are reversed by genetic immunizations augmented with cytokine-ex- pressing plasmids. J Immunol 1997;159:5107-5113. 30. Kim WH, Hong F, Jaruga B, Hu Z, Fan S, Liang TJ, Gao B. Additive activation of hepatic NF-kappaB by ethanol and hepatitis B protein X (HBX) or HCV core protein: involvement of TNF-alpha receptor 1-inde- pendent and dependent mechanisms. FASEB J 2001;15:2551-2553. 31. Oshita T, Hayashi N, Kasahara A, Hagiwara H, Mita E, Naito M, Kata- yama K, et al. Increased serum hepatitis C virus RNA levels among alco- holic patients with chronic hepatitis C. HEPATOLOGY 1994;20:1115-1120. 32. Haydon GH, Jarvis LM, Blair CS, Simmonds P, Harrison DJ, Simpson KJ, Hayes PC. Clinical significance of intrahepatic hepatitis C virus levels in patients with chronic HCV infection. Gut 1998;42:570-575. 33. Soto B, Sanchez-Quijano A, Rodrigo L, Leal M, Lissen E. HIV infection modifies the natural history of chronic parenterally acquired heptitis C with an unusually rapid progression to cirrhosis. A multicenter study on 547 patients. J Hepatol 1997;26:1-5. 34. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, et al. Influence of human immunodeficiency virus coin- fection on chronic hepatitis C in injection drug users: a long-term retro- spective cohort study. HEPATOLOGY 2001;34:1193-1199. 35. Prieto M, Berenguer M, Rayon M, Cordoba J, Arg¨uello L, Carrasco D, Garcia-Herola A, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. HEPATOLOGY 1999;29:250-256. 36. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Cordoba J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-684. 37. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, Moya A, et al. Contribution of donor age to the recent decrease in patient survival among HVC-infected liver transplant recipients. HEPATOLOGY 2002;36:202-210. 38. Zeuzem S, Franka A, Lee JH, Herrmann G, R¨uster B, Roth WK. Phylo- genetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. HEPATOLOGY 1996;24:1003-1009. 39. Martinot-Peignoux M, Marcellin P, Gournay J, Gabriel F, Courtois F, Branger M, Wild AM, et al. Detection and quantitation of serum hepatitis C virus (HCV) RNA by branched DNA amplification in anti-HCV pos- itive blood donors. J Hepatol 1994;20:676-678. 40. Gervais A, Martinot M, Boyer N, Aupe´rin A, Le Breton V, Degott C, Valla D, et al. Quantitation of hepatic hepatitis C virus RNA with chronic hepatitis C, relationship with severity of disease, viral genotype and re- sponse to treatment. J Hepatol 2001;35:399-405. 41. Silini E, Bottellli R, Asti M, Bruno S, Candusso ME, Brambilla S, Bono F, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case control study. Gastroenterology 1996;111:199-205. 42. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999;31:(suppl 1):9-16. 43. Pawlotsky JM, Pellerin M, Bouvier M, Roudot-Thoraval F, Germanidis G, Bastie A, Darthuy E, et al. Genetic complexity of the hypervariable region 1 (HVR 1) of hepatitis C virus. Influence on the characteristics of the infection and the response to alpha-interferon therapy in patients with chronic hepatitis C. J Med Virol 1998;54:256-264. 44. Asselah T, Martinot M, Cazals-Hatem D, Boyer N, Aupe´rin A, Le Breton V, Erlinger S, et al. Hypervariable region 1 quasispecies in hepatitis C virus gentotype 1b and 3 infected patients with normal and abnormal serum alanine aminotransferase levels. J Viral Hepat 2002;9:29-35. 45. Smith BC, Grove J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. HEPATOLOGY 1998;27:1695-1699.

46. Adinolfi LE, Gambardella M, Andreana A, Tripodi M-F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. HEPATOLOGY 2001;33:1358-1364. 47. Hwang SJ, Luo JC, Chu CW, Lai CR, Lu CL, Tsay SH, Wu JC, et al. Hepatic steatosis in chronic hepatitis C virus infection: prevalence and clinical correlation. J Gastroenterol Hepatol 2001;21:190-195. 48. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates signifi- cantly with body mass index and steatosis. HEPATOLOGY 1999;29:1215- 1219. 49. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed non-alcoholic fatty liver disease. Liver 2001;21:266-271. 50. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, et al P. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detect- able serum hepatitis C virus RNA. HEPATOLOGY 2001;34:1000-1005. 51. Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Du- mouchel P, Cazier A, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. HEPATOLOGY 1998;27:868-872. 52. Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmen- tieri B, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118:760-764. 53. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine amino- transferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988;95:734-739. 54. Pohl A, Behling C, Olivier D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibro- sis in chronic hepatitis C virus infection. Am J Gastroenterol 2001;96: 3142-3146. 55. Imbert-Bismut, F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poy- nard T, for the MULTIVIRC group. Biochemical markers of liver fibrossis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075. 56. Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. HEPATOLOGY 1994;20:780-787. 57. Guechot J, Poupon RE, Poupon R. Serum hyaluronan as a marker of liver fibrosis. J Hepatol 1995;22:103-106. 58. Gabrielli GB, Capra F, Casaril M, Squarzoni S, Tognella P, Dagradi R, De Maria E, et al. Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis. Clin Chim Acta 1997;265:21-31. 59. Neuman MG, Benhamou JP, Bourli`ere M, Ibrahim A, Malkiewicz I, As- selah T, Martinot-Peignoux M, et al. Serum TNF-and TGF-levels in chronic hepatitis C patients are modulated by therapy. Cytokine 2002;17: 108-117. 60. Kasahara A, Hayashi N, Mochizuki K, Oshita M, Katayama K, Kato M, Masuzawara M, et al. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. J Hepatol 1997;26:574-583. 61. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashi- moto E, et al. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23:1334-1340. 62. Baroni GS, Pastorelli A, Manzin A, Beneddi A, Marucci L, Solforosi L, Di Sario, et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 1999;19:212-219. 63. Bedossa P, Paradis V, Lazure T. He´patites chroniques virales. In: La biopsie he´patique en pathologie non tumorale du foie. Groupe Metavir. Paris, France: Elsevier, 2000, p. 31.

Document info
Document views47
Page views47
Page last viewedMon Jan 23 13:14:53 UTC 2017